Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM

ABSTRACT: Like other previous treatments and approaches, sorafenib, an antiangiogenic drug, failed to show any benefit in the adjuvant setting for hepatocellular carcinoma in a large clinical trial. We discuss reasons and implications of these negative results and the implications for clinical pract...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouattour, Mohamed, Soubrane, Olivier, de Gramont, Armand, Faivre, Sandrine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124225/
https://www.ncbi.nlm.nih.gov/pubmed/27887632
http://dx.doi.org/10.1186/s13063-016-1675-8
_version_ 1782469822385225728
author Bouattour, Mohamed
Soubrane, Olivier
de Gramont, Armand
Faivre, Sandrine
author_facet Bouattour, Mohamed
Soubrane, Olivier
de Gramont, Armand
Faivre, Sandrine
author_sort Bouattour, Mohamed
collection PubMed
description ABSTRACT: Like other previous treatments and approaches, sorafenib, an antiangiogenic drug, failed to show any benefit in the adjuvant setting for hepatocellular carcinoma in a large clinical trial. We discuss reasons and implications of these negative results and the implications for clinical practice and future research. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00692770. Registered 5 June 2008. This study has been completed.
format Online
Article
Text
id pubmed-5124225
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51242252016-12-08 Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM Bouattour, Mohamed Soubrane, Olivier de Gramont, Armand Faivre, Sandrine Trials Letter ABSTRACT: Like other previous treatments and approaches, sorafenib, an antiangiogenic drug, failed to show any benefit in the adjuvant setting for hepatocellular carcinoma in a large clinical trial. We discuss reasons and implications of these negative results and the implications for clinical practice and future research. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00692770. Registered 5 June 2008. This study has been completed. BioMed Central 2016-11-25 /pmc/articles/PMC5124225/ /pubmed/27887632 http://dx.doi.org/10.1186/s13063-016-1675-8 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter
Bouattour, Mohamed
Soubrane, Olivier
de Gramont, Armand
Faivre, Sandrine
Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM
title Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM
title_full Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM
title_fullStr Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM
title_full_unstemmed Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM
title_short Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM
title_sort adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the storm
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124225/
https://www.ncbi.nlm.nih.gov/pubmed/27887632
http://dx.doi.org/10.1186/s13063-016-1675-8
work_keys_str_mv AT bouattourmohamed adjuvanttherapiesinadvancedhepatocellularcarcinomamovingforwardfromthestorm
AT soubraneolivier adjuvanttherapiesinadvancedhepatocellularcarcinomamovingforwardfromthestorm
AT degramontarmand adjuvanttherapiesinadvancedhepatocellularcarcinomamovingforwardfromthestorm
AT faivresandrine adjuvanttherapiesinadvancedhepatocellularcarcinomamovingforwardfromthestorm

Ejemplares similares